Treatment of COVID-19 Vaccine Resistant Migraine Attack with CGRP Monoclonal Antibody: A Case Report

Many researches have shown that coronavirus infection can lead to neurological symptoms. The most common symptom is headache. Calcitonin gene-related peptide (CGRP), which has an important role in the pathophysiology of migraine, may have an active role in persistent headaches after COVID, due to th...

Full description

Saved in:
Bibliographic Details
Published in:Noro-Psikiyatri Arsivi 2023-09, Vol.60 (3), p.292-294
Main Authors: Duman, Sanem Coşkun, Özkan, Esra, Özdemir, Yasemin Gürsoy
Format: Article
Language:English
Subjects:
Azorin (1873-1967)
Calcitonin
Case Report
Case reports
Causes of
Complaints
Coronaviruses
COVID-19 vaccines
Disease transmission
Drug dosages
Drug therapy
Headaches
Health aspects
Infection
Infections
Medical research
Medicine, Experimental
Migraine
Monoclonal antibodies
Neurology
Olfaction disorders
Pain
Pathophysiology
Patients
Peptides
Proteins
Severe acute respiratory syndrome coronavirus 2
Tumor necrosis factor-TNF
Viral infections
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many researches have shown that coronavirus infection can lead to neurological symptoms. The most common symptom is headache. Calcitonin gene-related peptide (CGRP), which has an important role in the pathophysiology of migraine, may have an active role in persistent headaches after COVID, due to the structural similarity between the CGRP receptor and the SARS-CoV-2 spike protein. In this case report, the effect of the anti-CGRP monoclonal antibody on the migraine attack occurring after COVID-19 m-RNA vaccine will be discussed. A 55-year-old female patient who is followed up with a diagnosis of chronic migraine, had severe and throbbing headache that started after the COVID-19 m-RNA vaccine. After galcanezumab (CGRP monoclonal antibody - CGRP mAb) was started in the patient whose complaints did not regress despite the adjustment of the current drug doses, clinically significant improvement was observed in her complaints after the first dose and it was planned to continue with 120 mg CGRP mAb per month in her follow-ups.
ISSN:1300-0667
1309-4866
DOI:10.29399/npa.28266